Clinical and prognostic significance of coagulation assays in gastric cancer

Journal of Gastrointestinal Cancer

Volumn 44, Issue 3, 2013, Pages 285-292

  Tas, Faruk ^a   Ciftci, Rumeysa ^a   Kilic, Leyla ^a   Serilmez, Murat ^a   Karabulut, Senem ^a   Duranyildiz, Derya ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Coagulation tests; Gastric cancer; Survival

Indexed keywords

D DIMER; FIBRINOGEN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING TEST; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STOMACH CANCER; THROMBOCYTE COUNT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION TESTS; CARCINOMA, SIGNET RING CELL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PLATELET COUNT; PROGNOSIS; PROTHROMBIN TIME; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84883219518     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-013-9490-x     Document Type: Article

References (44)

1. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-6.
2. Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987;18:275-84.
3. Kessler CM. The link between cancer and venous thromboembolism: a review. Am J Clin Oncol. 2009;32:S3-7.
4. Khorana AA. Risk assessment and prophylaxis for VTE in cancer patients. J Natl Compr Canc Netw. 2011;9:789-97.
5. Langer F, Holstein K, Eifrig B, Bokemeyer C. Haemostatic aspects in clinical oncology. Hämostaseologie. 2008;28:472-80.
6. Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol. 2003;1:673-8.
7. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388-94.
8. Ay C, Dunkler D, Pirker R, Thaler J, Quehenberger P, Wagner O, et al. High D-dimer levels are associated with poor prognosis in cancer patients. Haematologica. 2012;97:1158-64.
9. Siegel R, Naishadam D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
10. Kovacova E, Kinova S, Duris I, Remkova A. General changes in hemostasis in gastric cancer. Bratisl Lek Listy. 2009;110:215-21.
11. Rahr HB, Sørensen JV, Larsen JF, Jensen FS, Bredahl C. Markers of coagulation and fibrinolysis in portal blood from patients with and without gastric malignancy. Scand J Gastroenterol. 1994;29:516-21.
12. Yamamura T. Hematological disorders in patients with gastric cancer. Nihon Geka Gakkai Zasshi. 1984;85:675-85.
13. Di Micco P, Romano M, Niglio A, Nozzolillo P. Alteration of haemostasis in non-metastatic gastric cancer. Dig Liver Dis. 2001;33:546-50.
14. Fidan E, Kavgaci H, Orem A, Yilmaz M. Thrombin activatable fibrinolysis inhibitor and thrombin-antithrombin-III-complex levels in patients with gastric cancer. Tumour Biol. 2012;33:1519-25.
15. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009;27:4834-8.
16. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis. 2001;31 Suppl 1:11-5.
17. Eisenhauera EA, Therasseb P, Bogaertsc J, Schwartzd LH, Sargente D, Fordf R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
18. Tramecere I, Negri E, Pelucchi C. A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol. 2012;23:28-36.
19. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1038 patients. Ann Surg. 2000;232:362-71.
20. Glimelius B, Ekstrom K, Hoffman K. Randomised comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163-8.
21. Falanga A. Thrombophilia in cancer. Semin Thromb Haemost. 2005;31:104-10.
22. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: trousseau's syndrome revisited. Blood. 1983;62:14-31.
23. Bottasso B, Mari D, Coppola R, Santoro N, Vaglini M, Mannuci PM. Hypercoagulability and hyperfibrinogenemia in patients with melanoma. Thromb Res. 1996;81:345-52.
24. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in patient with lung cancer. Thorax. 1997;52:563-5.
25. Blackwell K, Haroon Z, Broadwater G, Berry D, Harris L, Iglehart JD, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600-8.
26. Szajda SD, Darewicz B, Gorzel M, Zalewska B, Skrzydlewski Z, Kudelski J, et al. Cancer procoagulant (CP). Przegl Lek. 2005;62:169-72.
27. Molnar S, Guglielmone H, Lavarda M, Rizzi ML, Jarchum G. Procoagulant factors in patients with cancer. Hematology. 2007;12:555-9.
28. Naito S, Inoue S, Kinjo M, Tanaka K. Thromboplastic and fibrinolytic activities of cultured human gastric cancer cell lines. Gann. 1983;74:240-7.
29. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. J Hematol. 2001;73:145-50.
30. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004;50:187-96.
31. Connoly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010;125:1-7.
32. Südhoff T, Schneider W. Fibrinolytic mechanisms in tumor growth and spreading. Clin Invest. 1992;70:631-6.
33. Tiutrin II, Karpov AB, Udut VV, Tsisik RM, Solokhina EA. Disorders of the hemostatic system in patients with disseminated stomach cancer. Vopr Onkol. 1989;35:460-5.
34. Abbasciano V, Tassinari D, Sartori S, Trevisani L, Arcudi D. Usefulness of coagulation markers in staging of gastric cancer. Cancer Detect Prev. 1995;19:331-6.
35. Prokopowicz J, Gabryelewicz A, Wołosowicz N, Szałaj W, Puchalski Z. Peripheral and gastric fibrinolysis in patients with gastric carcinoma. Z Exp Chir. 1975;8:309-12.
36. Kwon HC, Oh SY, Lee S, Kim SH. Plasma levels of prothrombin fragment F1 + 2, D-dimer and prothrombin time correlate with clinical stage and lymph node metastasis in operable gastric cancer patients. Jpn J Clin Oncol. 2008;38:2-7.
37. Mkrtchian LN, Shukurian SG, Sarkisian OM, Magakian AG. Blood coagulation disorders and tumor growth. Vopr Onkol. 1991;37:992-7.
38. Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost. 2003;29:291-300.
39. PavlovskiÄ DP. Disseminated intravascular coagulation syndrome (DIC) in stomach and intestinal cancer. Vopr Onkol. 1986;32:37-42.
40. Heimburger N, Pâques EP, Römisch J. Coagulation and fibrinolysis in cancer. Behring Inst Mitt. 1992;91:169-82.
41. Zorio E, Gilabert-Estellés J, España F, Ramón LA, Cosín R, Estellés A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem. 2008;15:923-9.
42. Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb Haemost. 2001;86:828-33.
43. Wada H, Mori Y, Okabayashi K, Gabazza EC, Kushiya F. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol. 2003;72:1-7.
44. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995;74:282-90.